The exacerbation of a co-existing autoimmune disease is often a concern for physicians who use immunomodulating agents for the treatment of a concomitant process. As physicians begin to treat chronic hepatitis C more often and more aggressively, this potential problem with occur more frequently. Herein we reported a case of reactivation of sarcoidosis occurring during the treatment of chronic hepatitis C, and we present a literature review of other centers' experiences with this problem. Depending upon the severity of the exacerbation and the type of organ involvement, reactivation of sarcoidosis may require discontinuation of the interferon therapy, with or without the use of additional steroids. The majority of patients, however, do not require the use of steroids. Interestingly, continuation of the interferon therapy in the presence of a mild-to-moderate exacerbation of sarcoidosis may be safe in a minority of patients with noncritical organ involvement.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s535-002-8133-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
End-stage heart failure and heart transplant in cardiac sarcoidosis: a case series.
Eur Heart J Case Rep
December 2024
Heart Failure and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138 Bologna, Italy.
Article Synopsis
- - Diagnosing cardiac sarcoidosis (CS) is difficult, often leading to heart transplantation (HT) as the last option, especially when immunosuppressive therapies fail in advanced cases.
- - The case study presents four patients, each with different symptoms and backgrounds, who ultimately required HT for their CS, revealing the condition's complexity and urgency.
- - There are significant mid- and long-term challenges following HT for CS, notably the need for careful management of immunosuppression to prevent rejection and recurrence of sarcoidosis.
: A HERV Turn-On for Autoimmunity, Neurodegeneration, and Cancer?
Microorganisms
September 2024
Department of Biomedical Science, University of Sassari, 07100 Sassari, Italy.
Human endogenous retroviruses (HERVs) are remnants of ancient retroviral infections that, over millions of years, became integrated into the human genome. While normally inactive, environmental stimuli such as infections have contributed to the transcriptional reactivation of HERV-promoting pathological conditions, including the development of autoimmunity, neurodegenerative disease and cancer. What infections trigger HERV activation? subspecies (MAP) is a pluripotent driver of human disease.
View Article and Find Full Text PDFCo-Occurring Infections in Cancer Patients Treated with Checkpoint Inhibitors Significantly Increase the Risk of Immune-Related Adverse Events.
Cancers (Basel)
August 2024
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.
Therapeutic antibodies designed to target three immune checkpoint proteins have been applied in the treatment of various malignancies, including small and non-small cell lung cancers, melanoma, renal cell carcinoma, and others. These treatments combat cancers by reactivating cytotoxic T cells. Nevertheless, this mode of action was found to be associated with a broad range of immune-related adverse events (irAEs), including pneumonitis, sarcoidosis, myocarditis, nephritis, colitis, and hepatitis.
View Article and Find Full Text PDFDisseminated, fatal reactivation of bovine tuberculosis in a patient treated with adalimumab: a case report and review of the literature.
Infection
August 2024
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
Article Synopsis
- Tumor necrosis factor inhibitors (TNFi), like adalimumab, can increase the risk of tuberculosis (TB) reactivation; however, instances of Mycobacterium bovis infections are rare.
- A case involved a 78-year-old woman with M. bovis-related disseminated TB, which was initially misdiagnosed as sarcoidosis, and resulted in her death despite a negative TB test (IGRA) before treatment with TNFi.
- The study emphasizes the need for careful consideration of TB risks in immunosuppressed patients, highlighting the importance of patient history regarding potential exposure to unpasteurized dairy products, even in regions officially free of bovine TB.
Cushing's disease is a rare severe neuroendocrine disorder caused by chronic overproduction of adrenocorticotropic hormone by a pituitary tumor. Supraphysiological concentrations of cortisol in endogenous hypercortisolism have an immunosuppressive and anti-inflammatory effect similar to therapy with systemic glucocorticosteroids. This may reduce the activity of the patient's concomitant autoimmune inflammatory diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!